• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

References for Acquired Bleeding

1. Hoffbrand AV, Moss PAH, Pettit JE. Thrombosis and antithrombotic therapy. Essential Haematology. 5th ed: Blackwell Publishing, Inc., 2009:303–19.

2. White HD, Gersh BJ, Opie LH. Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. In: Opie LH, Gersh BJ, editors. Drugs for the Heart. 6th ed: Elsevier Saunders, 2005:275-319.

3. Autar R. New Oral Anticoagulants to Revolutionize Venous Thromboembolism (VTE) Management. J Orthop Nurs 2009;13:165-71.

4. Hoffbrand AV, Moss PAH, Pettit JE. Platelets, blood coagulation and haemostasis. Essential Haematology. 5th ed: Blackwell Publishing, Inc., 2009:264–77.

5. Fitzmaurice DA, Blann AD, Gregory YH. ABC of antithrombotic therapy. Bleeding risks of antithrombotic therapy. BMJ 2002;325(7368):828–31.

6. Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications - clinical presentation and therapeutic options. Thromb Res 2008;122 Suppl 2:S13-8.

7. Vigue B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007;33(4):721-5.

8. Esmerio FG, Souza EN, Leiria TL, Lunelli R, Moraes MA. Constant Use of Oral Anticoagulants: Implications in the Control of Their Adequate Levels. Arq Bras Cardiol 2009;93(5):508–12.

9. Koo S, Kucher N, Nguyen PL, Fanikos J, Marks PW, Goldhaber SZ. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med 2004;164(14):1557-60.

10. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006;4(5):967-70.

11. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol 2001;114(2):271-80.

12. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001;115(4):998-1001.

13. Wilson SE, Douketis JD, Crowther MA. Treatment of warfarin-associated coagulopathy: a physician survey. Chest 2001;120(6):1972-6.

14. Hanley JP. Warfarin reversal. J Clin Pathol 2004;57(11):1132-9.

15. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. British Society for Haematology 2005;132:277-85.

16. Management of Vitamin K Antagonist Overdosage, Hemorrhage Risk Situations, and Hemorrhagic Events in Patients Treated with Oral Anticoagulants in the Community and in Hospitals: Board of the French National Authority for Health (HAS) 2008.

17. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):160S - 98S.

18. Bruce D, Nokes TJC. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care 2008;12:1-7.

19. Ozgonenel B, O'Malley B, Krishen P, Eisenbrey AB. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007;82(12):1091-4.

20. Wilson SE, Watson HG, Crowther MA. Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. CMAJ 2004;170(5):821-4.

21. Vigue B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care 2009;13(2):209.

22. Heise D, Brauer A, Quintel M. Recombinant activated factor VII (Novo7) in patients with ventricular assist devices: case report and review of the current literature. J Cardiothorac Surg 2007;2:47.

23. Chiara O, Cimbanassi S, Brioschi PR, Bucci L, Terzi V, Vesconi S. Treatment of critical bleeding in trauma patients. Minerva Anestesiol 2006;72(6):383-7.

24. Koh MB, Hunt BJ. The management of perioperative bleeding. Blood Rev 2003;17(3):179-85.

25. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sorensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008;101(6):769-73.

26. Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth 2010;105(2):116-21.

27. Danes AF, Cuenca LG, Bueno SR, Mendarte Barrenechea L, Ronsano JB. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008;94(3):221-6.

28. Fenger-Eriksen C, Ingerslev J, Sorensen B. Fibrinogen concentrate--a potential universal hemostatic agent. Expert Opin Biol Ther 2009;9(10):1325-33.

29. Hunt BJ, Segal H. Hyperfibrinolysis. J Clin Pathol 1996;49:958.

30. Peyvandi F, Palla R. Fibrinogen concentrates. Clin Adv Hematol Oncol 2009;7(12):788-90.

31. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009;108(5):1433-46.

32. Sie P, Steib A. Central laboratory and point of care assessment of perioperative hemostasis. Can J Anesth 2006;53(6):S12–20.

33. Enriquez LJ, Shore-Lesserson L. Point-of-care coagulation testing and transfusion algorithms. Br J Anaesth 2009;103 Suppl 1:i14-22.

34. Urwyler N, Trelle S, Theiler L, Juni P, Staub LP, Luyet C, et al. Does point of care prothrombin time measurement reduce the transfusion of fresh frozen plasma in patients undergoing major surgery? The POC-OP randomized-controlled trial. Trials 2009;10:107.

35. Borgman M SP, Perkins J et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007;63:805-13.

36. The Society of Thoracic Surgeons Blood Conservative Guideline Task Force. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline. Ann Thorac Surg 2007;83:S27-86.

37. Duchesne J HJ, Wahl G et al. Review of Current Blood Transfusions Strategies in a Mature Level I Trauma Center: Were We Wrong for the Last 60 Years? J Trauma 2008;65:272-78.

38. Nascimento B CJ, Rubenfeld G et al. Clinical review: Fresh frozen plasma in massive bleedings - more questions than answers. Critical Care 2010;14:202-10.

39. Avidan MS, Alcock EL, Da Fonseca J, Ponte J, Desai JB, Despotis GJ, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004;92(2):178-86.

40. Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM(R))-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010;14(2):R55.

41. Ridley S, Taylor B, Gunning K. Medical management of bleeding in critically ill patients. Cont Edu Anaesth Crit Care & Pain 2007;7(4):116-21.

42. AnaesthesiaUK. Blood products, 2009.

43. Novo Nordisk. NovoSeven SPC, 2009.

44. Rahe-Meyer N, Pichlmaier M, Haverich A, Solomon C, Winterhalter M, Piepenbrock S, et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009;102(6):785-92.

45. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):204S-33S.

46. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Critical care (London, England) 2008;12(4):R105.

47. Lorenz R, Kienast J, Otto U, Egger K, Kiehl M, Schreiter D, et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003;15(1):15-20.

48. Schick KS, Fertmann JM, Jauch KW, Hoffmann JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Critical care (London, England) 2009;13(6):R191.

49. Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B, et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive care medicine 1999;25(10):1105-10.

50. Schoechl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Critical care (London, England);14(2):R55.

51. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010;14(2):R52.

52. Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010;14(2):R55.

53. Nutesco E, Shapiro N, Chevalier A, Amin A. A pharmacological overview of current and emerging anticoagulants. Cleveland Clinic Journal of Medicine 2012; 72 Suppl 1:S2-S6.

54. Battinelli E. Reversal of new oral anticoagulants. American Heart Association, 2011; 124:1508-1510.

55. Meisbach W, Siefried E. New direct oral anticogulants - current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012; 108.

56. Samama 2011

57. Connolly S et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2009; 361(12):1139-1151

58. Granger C et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2011; 365(11):981-992

59. Patel M et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEJM.org (10.1056/NWJMoa1009638); [Original Source: New England Journal of Medicine (August 10, 2011)].

60. Camm A, Lip G, Caterina R, Savelieva I, Atar D, Hohnloser S, Hindricks G, Kirchhof P. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. European Heart Journal (doi:10.1093/eurheartj/ehs253); 2012.

61. Levy J, Faraoni D, Spring J, Douketis J, Samama C. Managing new oral anticoagulants in the perioperative and intensive care setting. Anesthesiology 2013; (118)00-00.

62. Perzborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. (PP-MO-183) 2009.

63. Zou W, Zorn M, Nawroth P, Bütehorn U, Perzborn E, Heitmeier S, Veltkamp R. Hemostatic therapy in experimental intracerebral hemorrhage associated with Rivaroxaban. American Heart Association, 2013; DOI: 10.1161/STROKEAHA.112.675231.

64. van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of Dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. 2011.

65. Zhou W et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor Dabigatran. Journal of the American Stroke Association, 2011; DOI: 10.1161/STROKEAHA.111.624650.

66. Pragst I, Zeitler S, Doerr B, Kaspereit F, Herzog E, Dickneite G, Van Ryn J. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10:1841-1848.

Last Updated: 10/31/2014 4:16 PM
  • E-mail
  • Print
  • Share